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Background: Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung
cancer (NSCLC). These two agents have different mechanisms of action. Combined treatment with erlotinib and
pemetrexed could potentially augment the antitumor activity of either agent alone. In the present study, we
investigated the safety profile of combined administration of the two agents in pretreated NSCLC patients.
Methods: A phase I dose-finding study (Trial registration: UMIN000002900) was performed in patients with stage
III/IV nonsquamous NSCLC whose disease had progressed on or after receiving first-line chemotherapy. Patients
received 500 mg/m2 of pemetrexed intravenously every 21 days and erlotinib (100 mg at Level 1 and 150 mg at
Level 2) orally on days 2–16.
Results: Twelve patients, nine males and three females, were recruited. Patient characteristics included a median
age of 66 years (range, 48–78 years), stage IV disease (nine cases), adenocarcinoma (seven cases) and activating
mutation-positives in the epidermal growth factor receptor gene (two cases). Treatment was well-tolerated, and the
recommended dose of erlotinib was fixed at 150 mg. Dose-limiting toxicities were experienced in three patients
and included: grade 3 elevation of serum alanine aminotransferase, repetitive grade 4 neutropenia that required
reduction of the second dose of pemetrexed and grade 3 diarrhea. No patient experienced drug-induced interstitial
lung disease. Three patients achieved a partial response and stable disease was maintained in five patients.
Conclusions: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with
promising efficacy against pretreated advanced nonsquamous NSCLC.
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Lung cancer is the leading cause of cancer-related death
worldwide [1]. Non-small-cell lung cancer (NSCLC)
accounts for approximately 85% of all lung cancer cases.
Most of these cases are found to have locally advanced or
systemically metastasized disease at the time of diagnosis.
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reproduction in any medium, provided the orused in combination with one of the third-generation
agents are recommended as the standard first-line treat-
ment for advanced NSCLC, based on evidence of
improved survival and quality of life (QOL) [2-5]. How-
ever, the efficacy of these first-line regimens has reached
a plateau. Although currently docetaxel, pemetrexed and
erlotinib have been approved for second-line treatment,
only about 10% of patients respond to monotherapy using
any of these agents [6-8]. To date, combination of cyto-
toxic drugs has also not been shown to provide a survival
benefit in a second-line setting. Indeed, combination ther-
apy causes excessive toxicities, which often make itLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spective of any additive antitumor effect.
Pemetrexed (AlimtaW) is a multi-targeting antifolate
cytotoxic agent that mainly inhibits three key enzymes
involved in folate metabolism, namely thymidylate syn-
thase, dihydrofolate reductase and glycinamide ribonu-
cleotide formyl transferase [9]. When exposed to
pemtrexed, a broad spectrum of solid cancer cells are
arrested, mainly in the S-phase, and subsequently be-
come apoptotic. A phase III trial in a second-line setting
demonstrated that pemetrexed significantly improved
tolerability, while maintaining an equivalent survival
benefit as compared with docetaxel in pretreated
NSCLC patients [7]. Because doses of pemetrexed as
high as 1000 mg/m2 have not been found to be superior
to a dose of 500 mg/m2 in terms of efficacy, the recom-
mended dose (RD) has been fixed at this lower level
[10,11]. Pemetrexed became available in Japan for the
treatment of NSCLC at the approved dose of 500 mg/m2
in May 2009.
Erlotinib (TarcevaW), an oral and reversible epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI), causes cell growth arrest in the G1-phase and
induces apoptosis in a variety of tumor cells [12]. The
pivotal BR.21 study showed that erlotinib brought a sur-
vival benefit with delayed progression of symptoms and
improvement of QOL in a wide range of NSCLC
patients, irrespective of EGFR mutation status [8]. Erloti-
nib became available in Japan for the treatment of
relapsed NSCLC at an approved daily dose of 150 mg in
October 2007.
Pemetrexed and erlotinib have advantages over doce-
taxel in that they have a better toxicity profile and more
favorable tolerability. Since these two agents have differ-
ent mechanisms of action and minimum overlap toxici-
ties, their combination is expected to offer synergistic
antitumor efficacy without increased toxicity. However,
based on preclinical in vitro findings, careful attention
should be paid to the combined administration schedule
for pemetrexed and erlotinib. It was found that, when
human NSCLC cells were exposed to pemetrexed fol-
lowed by erlotinib, erlotinib synergistically potentiated
the cytotoxic effect of pemetrexed [13,14]. This cytotoxic
synergism was observed in both erlotinib-sensitive and -
resistant cell lines. In this order of administration, peme-
trexed induced cells to accumulate in the M-phase
where erlotinib is most cytotoxic. Hence, this sequential
combination enhances antitumor activity. In contrast,
when NSCLC cells were treated with these agents in re-
verse order, antagonistic interaction was observed. This
was due to the fact that erlotinib induced G1 arrest,
resulting in a reduction in the number of cell entering
the S-phase, the crucial cell cycle phase for the exertion
of pemetrexed-mediated cytotoxicity [13,14]. A similarfinding has been reported for the combination of erloti-
nib with docetaxel [15].
Assessment of treatment-related adverse events (AEs)
associated with the pemetrexed-erlotinib combination
is important for future clinical application, side by side
with evaluation of the expected additive antitumor
effects. EGFR-TKIs have different toxicity profiles be-
tween Asians and Caucasians. EGFR-TKI-induced
interstitial lung disease is observed more frequently in
Asians, especially in the Japanese. Increased
hematologic toxicities have been reported in a recent
phase I study of combination therapy involving gefiti-
nib and vinorelbine [16]. Therefore, a safety evaluation
in Japanese patients will inevitably be required for the
combination of EGFR-TKI with cytotoxic drugs.
Hence, we conducted a phase I trial to determine the
dose-limiting toxicity (DLT) and to establish a recom-
mended dose (RD), by estimating the maximum toler-
ated dose (MTD) of the combination of pemetrexed
and intermittent erlotinib in a second-line setting for




The following eligibility criteria were mandatory for pa-
tient enrollment: (1) histologically or cytologically con-
firmed stage IIIB/IV nonsquamous NSCLC which had
progressed on or after first-line platinum-based chemo-
therapy; (2) age ≥ 20 years; (3) measurable disease accord-
ing to Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1; (4) an Eastern Cooperative Onco-
logy Group (ECOG) performance status (PS) grade of
0–1; (5) adequate hematologic (absolute white blood cell
count≥ 3000/μL, neutrophil count≥ 1500/μL, platelet
count≥ 100000/μL and hemoglobin≥ 9.0 g/dL), renal
(serum creatinine≤ 1.5 times the institutional upper limit
of normal [ULN]), liver (serum bilirubin≤ 1.5 mg/dL
and aminotransferases ≤ 2.0 times that of the ULN),
and respiratory (SpO2 ≥ 90% under room air) functions;
(6) estimated life expectancy of more than 3 months;
and (7) provision of written informed consent. Patients
with asymptomatic brain metastases were also eligible.
On the other hand, patients who had previously received
HER-targeted therapy or pemetrexed were excluded.
Patients with clinically significant ophthalmologic abnor-
malities or other disorders that might increase the risk
of corneal epithelial injury were also excluded. In
addition, patients who were pregnant or had unstable
medical conditions were excluded. Patients with child-
bearing potential were required to use a medically ac-
ceptable contraceptive. Also considered ineligible were
patients that had undergone invasive therapeutic proce-
dures including pleurodesis and intrathoracic drainage
Table 1 Patient characteristics (n = 12)













Best response to prior chemo
PR/SD/PD/NE 3/5/3/1
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radiotherapy within 12 weeks or extra-thoracic radio-
therapy within 2 weeks.
Study design and treatment plan
This open-label phase I dose-finding study evaluated the
safety dose of erlotinib in combination with pemetrexed
for a future phase II study. The primary objective was to
determine the RD of erlotinib combined with the fixed
dose (500 mg/m2) of pemetrexed and the DLTs. The sec-
ondary objective was to evaluate the safety profile. The
study was carried out in Osaka Police Hospital and
Osaka University Hospital after the protocol was
approved by each institutional review board. The study
protocol adhered to the principles outlined in the Guide-
line for Good Clinical Practice and Declaration of Hel-
sinki and the trial was registered as UMIN000002900.
Written informed consent was obtained from all patients
before commencement of the study.
Patients were scheduled to receive 500 mg/m2 of
pemetrexed intravenously on day 1, and erlotinib at a
dose of 100 mg at Level 1 and 150 mg at Level 2, orally
from days 2–16. Patients were also supplemented with
1 mg of vitamin B12 intramuscularly every 9 weeks and a
daily dose of 500 μg of folic acid orally. The treatment
cycle was repeated every 21 days with permission of
delay up to 14 days until the first appearance of un-
acceptable toxicity, disease progression or death. The
dose escalation followed the standard ‘3 + 3’ rule. When
none of the first three patients experienced a DLT at the
Level 1 dose, three patients were treated at the Level 2
dose. If at least one of three of the first cohort in each
level encountered a DLT, an additional cohort of three
patients was evaluated at the same dose. No intrapatient
dose escalation was permitted.
Definition of DLT and MTD
DLTs were defined in advance as any of the following
drug-related toxicities that occurred within the first two
cycles: (1) grade 4 neutropenia lasting 7 days and longer;
(2) febrile neutropenia lasting 7 days and longer; (3)
grade 4 thrombocytopenia or requirement for platelet
transfusion; (4) delay in the start of the next course of
longer than 2 weeks due to prolonged toxicity; (5) grade
3 or 4 non-hematologic toxicity excluding hyponatremia,
skin rash, nausea and vomiting; (6) necessity for more
than one dose reduction in pemetrexed or erlotinib. The
dose with which more than one third of patients experi-
enced any DLT was considered as the MTD. The avail-
able maximum doses approved by health insurance in
Japan were 150 mg for erlotinib and 500 mg/m2 for
pemetrexed. The purpose of this study was to examine if
erlotinib could enhance the antitumor activity of peme-
trexed. Moreover, erlotinib beyond a dose of 150 mg isknown to increase the incidence of severe AEs that
would probably interfere with the administration of
pemetrexed. For these reasons, dose escalation beyond
the approved maximum doses was not planned even if
they did not reach the MTD.
Patient assessments
Patients underwent weekly physical examination and as-
sessment of the following parameters: vital signs, PS,
hematology and biochemistry. Before each cycle, the
patient’s medical history was reviewed. All AEs and
DLTs were reported throughout the study. Toxicity was
graded according to the National Cancer Institute Com-
mon Terminology Criteria for AEs (CTCAE) version 3.0.
Although not the primary endpoint of this phase I study,
treatment efficacy was also assessed in accordance with
RECIST version 1.1 and the best overall response was
evaluated. Tumor size was calculated using computed
tomography images at time points within 4 weeks be-
fore, and 4 and 8 weeks after initiation of the therapy




Twelve patients (Level 1, n = 6; Level 2, n = 6) were en-
rolled from two institutes between August 2009 and
March 2011. The antitumor efficacy and RD data were
finalized at the end of May 2011. All patients were also
assessable for AEs, DLTs and best overall responses. The
baseline characteristics of the nine male and three fe-
male patients (Table 1) where: median age 66 years
(range, 48 to 78 years); PS grade 1 (nine cases); stage IV
disease (nine cases); and one current and eight ex-
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omas, one large cell carcinoma and four poorly differen-
tiated NSCLCs without the components of squamous
cell carcinoma. EGFR mutations were also examined
using the peptide nucleic acid-locked nucleic acid PCR
clamp method in all patients. Two had activating point
mutations G719S in exon 18 and L858R in exon 21.
Safety, DLT and RD
Almost all patients experienced AEs to some extent re-
gardless of causality and severity. As summarized in
Table 2, dermal, gastrointestinal and hematologic disor-
ders were frequently observed AEs. Severe AEs with
grade 3/4 were neutropenia/leukopenia (n = 2), diarrhea
(n = 1), skin rash (n = 1), pruritus (n = 2) and alanine ami-
notransferase (ALT) elevation (n = 1). At Level 1, one pa-
tient in the first cohort (n = 3) developed a DLT of grade
3 ALT elevation. Another patient in the second cohortTable 2 Adverse events in patients with advanced non-
small cell lung cancer treated with erlotinib and
pemetrexed
Level 1 (n = 6) Level 2 (n = 6)
Hematologic G1 G2 G3 G4 G1 G2 G3 G4
Neutropenia/Leukopenia 2 0 0 1 0 0 0 1
Thrombocytopenia 2 1 0 0 1 1 0 0
Anemia 3 3 0 0 4 1 0 0
Non-Hematologic G1 G2 G3 G4 G1 G2 G3 G4
Nausea 3 0 0 0 2 1 0 0
Vomit 1 0 0 0 0 0 0 0
Anorexia 3 1 0 0 2 1 0 0
Malaise 1 1 0 0 0 0 0 0
Fatigue 2 1 0 0 3 0 0 0
Diarrhea 1 0 0 0 1 0 1 0
Constipation 1 0 0 0 2 0 0 0
Hiccup 0 0 0 0 0 1 0 0
Oral mucositis 1 0 0 0 3 0 0 0
Rash 2 2 1 0 1 5 0 0
Pruritus 1 0 1 0 2 0 1 0
Paronychia 0 0 0 0 2 0 0 0
Alopecia 0 0 0 0 1 0 0 0
Peripheral Edema 0 0 0 0 0 1 0 0
Alb 4 1 0 0 1 2 0 0
AST 4 2 0 0 3 1 0 0
ALT 0 3 1 0 2 2 0 0
ALP 2 0 0 0 2 1 0 0
Bilirubin 1 0 0 0 2 1 0 0
Na 0 0 0 0 3 0 0 0
K 2 0 0 0 1 0 0 0(n = 3) experienced a DLT of repetitive grade 4 neutro-
penia that required a successive dose reduction of peme-
trexed and termination of the treatment protocol. At
Level 2, one patient in the first cohort (n = 3) developed
a DLT of grade 3 diarrhea, which was probably caused
by erlotinib, because it did not recur during post-
protocol pemetrexed monotherapy. No patient in the
second cohort (n = 3) experienced DLTs. In total, three
out of 12 patients, two at Level 1 and one at Level 2,
experienced DLTs. The MTD, defined as the dose at
which more than one third of patients experience DLTs,
was not reached. Finally, the RD for erlotinib was fixed
at 150 mg.
Causes for discontinuation of protocol treatment
Eight patients had discontinued the treatment protocol
by the time of analysis. The reasons for withdrawal were
disease progression (n = 3), DLT (n = 1), patient’s refusal
to continue treatment (n = 2) and physician’s decision to
terminate treatment (n = 2). Four patients are still on the
treatment protocol. The median number of treatment
courses was 3.5 (range, 1 to 15). Among the three DLTs,
repetitive grade 4 neutropenia requiring a second dose
reduction of pemetrexed automatically meant the ter-
mination of the study protocol. The DLT of grade 3 ALT
elevation was thought to have been caused by erlotinib
and on the basis of a decision made by a physician the
patient was withdrawn from the study. However, the
DLT recurred during a following post-protocol course of
pemetrexed monotherapy at a dose of 500 mg/m2, and
was thereafter ameliorated by reducing the dose to
375 mg/m2. We concluded that this AE was attributable
to pemetrexed, and not to erlotinib. The patient who
experienced the other DLT of grade 3 diarrhea refused
to continue the therapy, although the DLT had improved
to grade 2 and the protocol permitted a resumption of
the therapy with a reduced dose of erlotinib (100 mg)
and pemetrexed (375 mg/m2) in the next cycle. One pa-
tient at Level 1 was withdrawn from the study due to a
physician’s decision, on the grounds that cancer-related
pain caused by invasion of the primary tumor into the
vertebrae had gradually worsened, while tumors had
maintained stable disease (SD) in line with RECIST after
nine cycles of treatment. One patient in Level 2 refused
to continue the therapy after three cycles because of
grade 2 peripheral edema.
Antitumor efficacy
All patients were evaluated for response to the treatment
protocol. Three achieved a partial response (PR), five
maintained SD, three had disease progression and one,
who was withdrawn from the study because of diarrhea
in the first cycle, was not evaluable (NE). Thus, the best
overall response rate (RR) and disease control rate
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10 patients without the activating EGFR mutation, three
(30.0%) achieved a PR and three (30.0%) had SD. On the
other hand, both of the two EGFR mutation-positive
patients maintained SD. One with G719S in exon 18
maintained SD for longer than 6 months. The other with
L858R in exon 21 showed a remarkable shrinkage in the
shorter axis of the measurable tumor, but did not meet
the PR criteria defined by the longest axis, and the dis-
ease was also stable for longer than 6 months.
Discussion
Two phase I clinical trials that have investigated the
safety and efficacy of the erlotinib-pemetrexed combin-
ation have been reported. In the first study by Ranson
et al. [17], where both agents were started on the same
day, DLTs were not experienced at doses of up to
150 mg/day of erlotinib plus 600 mg/m2 of pemetrexed;
the RD was determined as being equal to each of the
licensed single-agent doses (150 mg daily and 500 mg/m2
every 21 days, respectively). In the second study by
Davies et al. [18], the RD and administration schedule
was fixed at a dose of 250 mg from day 2 to 16 for erloti-
nib and 500 mg/m2 on day 1 for pemetrexed every
21 days. We used the same RD as in the first trial with an
identical administration schedule to that used in the sec-
ond trial, and have now moved to an ongoing phase II
trial.
As for the safety profile, observed AEs were consist-
ent with those reported in the former two phase I stud-
ies [17,18]. The most frequent AE was skin/dermal
disorder, which was compatible with that reported in
the previous studies of erlotinib monotherapy [19,20].
Other major AEs were hematologic disorders, ALT ele-
vation and gastrointestinal disorders, which were com-
monly observed in monotherapy involving either agent.
However, the majority of them were grade 1/2 and con-
trollable. Additive toxicities of erlotinib and pemetrexed
administered in combination seemed to be marginal
compared with those observed in previous studies of ei-
ther agent alone [11,19,20]. No patient experienced
interstitial lung disease. Consequently, administrating
intermittent erlotinib with pemetrexed was shown to be
safe and tolerable.
The latest randomized phase II study involving pre-
treated nonsquamous NSCLC patients demonstrated
that, as compared with pemetrexed (500 mg/m2, day 1)
alone, combination of pemetrexed (500 mg/m2, day 1)
with daily erlotinib (150 mg) significantly improved
both median progression-free survival (3.2 months vs.
2.9 months; p <0.01) and overall survival (11.8 months
vs. 7.8 months, p= 0.019), although the RR (17.1% vs.
10.8%) and DCR (55.8% vs. 51.8%) did not differ be-
tween the single and combined treatments [21]. Eventhough the design of this study differed from ours in
that the erlotinib administration schedule was daily ra-
ther than intermittent, and that collection of EGFR
mutation status data was discretionary rather than
mandatory, the significant survival benefit brought
about by this combination therapy has encouraged us
to continue our ongoing phase II study until we have
overall survival data.
When evaluated on the basis of RECIST two EGFR-
mutated patients did not respond in our study. How-
ever, one patient with a L858R mutation in exon 21
practically achieved a PR. The other with a G719S mu-
tation in exon 18 succeeded in maintaining a long SD,
which was also practically beneficial, considering that in
patients with the G719X mutation the reported RR to
EGFR-TKIs was approximately 56% [22]. Collectively,
the erlotinib and pemetrexed combination is not only
well-tolerated, but also attractive in terms of antitumor
efficacy, regardless of EGFR mutation status.
However, our study had a number of limitations. First,
pharmacokinetic analysis of the two agents was not con-
ducted and potential interactions were not investigated.
Second, QOL was not assessed by questionnaire. QOL
assessment would have been helpful in understanding
the impact of AEs, since there was a high rate of them
even though most were grade 1 or 2. These issues
should be addressed in future trials.
Recently, maintenance therapy following platinum-
doublet front-line therapy has been approved, as long as
the treatment regimen has tolerable and noncumulative
toxicity profiles. Pemetrexed and erlotinib have been
shown to be effective and tolerable when used as single-
agent maintenance therapy [23,24], and were approved
as suitable agents for this purpose by the US-Food and
Drug Administration in 2009 and the European Medi-
cines Agency in 2010. Since we have now demonstrated
the safety and possible efficacy of the combined use of
these two agents in the current phase I study, it would
be very interesting to compare the therapeutic efficacy
of this combination with that of the two agents adminis-
tered separately in a maintenance setting in the near
future; no studies of this design have been reported
to date.
In conclusion, the present study indicated that inter-
mittent erlotinib (150 mg on days 2 to 16) in combin-
ation with pemetrexed (500 mg/m2 on day 1) when
administered every 21 days is a feasible and well-
tolerated regimen. A multi-centered, single-arm phase II
study is currently ongoing to evaluate the efficacy and
safety of this combination regimen.
Conclusions
In the present study, combination chemotherapy with
intermittent erlotinib and pemetrexed was found to be
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could have additive antitumor effects against pretreated
advanced nonsquamous NSCLC. Further investigation
to substantiate the antitumor efficacy and safety of this
combination regimen in a higher number of patients is
currently ongoing in a phase II trial.
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